pharma · Relapsed or Refractory Multiple Myeloma (RRMM) · Relapsed and/or Refractory Multiple Myeloma
Celgene
Celgene Europe Limited
Celgene clinical programs — 45 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 2,104
- Programs
- 45
- Drugs
- 91
- Patents
- 0
Celgene projects
45 ClinicalTrials.gov programs sponsored by Celgene.
Celgene has 45 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ACE-536-LTFU-001
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial -
ACE-536-MF-002
Celgene Europe Limited
Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)
1 trial -
BB2121-MM-003
Celgene Europe Limited
Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.
1 trial -
CA0561060
Celgene Europe Limited
Myelodysplastic syndrome
1 trial -
CA057-001
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-1019
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CA071-1000
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
CA073-1003
Celgene Europe Limited
Relapsed/Refractory Follicular Lymphoma
1 trial -
CA073-1020
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
CA088-1007
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
CC-220-MM-002
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Cendakimab
Celgene Europe Limited
Eosinophilic esophagitis
1 trial -
FEDR-MF-002
Celgene Europe Limited
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
1 trial -
IM047-023
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Lenalidomide
Celgene Europe Limited
B-cell Chronic Lymphocytic Leukemia
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Ozanimod, Ozanimod
Celgene Europe Limited
Ulcerative colitis
1 trial -
RPC01-3203
Celgene Europe Limited
Moderately to Severely Active Crohn's Disease
1 trial -
Thalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
ACE-536
Celgene Europe Limited
Beta-Thalassemia
1 trial -
AG-221-AML-005
Celgene Europe Limited
Acute Myeloid Leukemia (AML)
1 trial -
CA057-003
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA057-1040
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
CA058-002
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CA061-1011
Celgene Europe Limited
Lupus Nephritis, Systemic Lupus Erythematosus
1 trial -
CA073-1022
Celgene Europe Limited
Newly Diagnosed Advanced Stage Follicular Lymphoma
1 trial -
CC-220-MM-001
Celgene Europe Limited
Multiple Myeloma
1 trial -
CC-486-NSCL-001
Celgene Europe Limited
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
CC-92480-MM-001
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM)
1 trial -
CC-92480-MM-002
Celgene Europe Limited
Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
1 trial -
CC-99282-NHL-001
Celgene Europe Limited
Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
1 trial -
IM045-1018
Celgene Europe Limited
Multiple Sclerosis Spasticity
1 trial -
JCAR017
Celgene Europe Limited
Lymphoma, Non-Hodgkin
1 trial -
Lisocabtagene maraleucel
Celgene Europe Limited
Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
1 trial -
Pomalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
idecabtagene vicleucel
Celgene Europe Limited
Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)
1 trial -
CA059-001
Celgene Europe Limited
Acute Myeloid Leukemia and Myelodysplastic Syndromes
1 trial -
CA061-1001
Celgene Europe Limited
Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)
1 trial -
CA061-1006
Celgene Europe Limited
Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)
1 trial -
CA1190002
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CC-486
Celgene Europe Limited
Leukemia, Myeloid, Acute
1 trial -
CC-90010-GBM-002
Celgene Europe Limited
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection
1 trial -
CC-90010-ST-001
Celgene Europe Limited
Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)
1 trial -
CC-90011-SCLC-001
Celgene Europe Limited
extensive stage small cell lung cancer
1 trial -
pomalidomide
Celgene Europe Limited
Multiple Myeloma in Relapse
1 trial
Frequently asked questions
How many clinical projects does Celgene have?
45 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.